Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium.
Acquired Immunodeficiency Syndrome
/ drug therapy
Adolescent
Africa, Central
Africa, Eastern
Africa, Southern
Age Distribution
Anti-HIV Agents
/ therapeutic use
Asia, Southeastern
Caribbean Region
Central America
Child
Child, Preschool
Cohort Studies
Databases, Factual
Female
HIV Infections
/ drug therapy
Humans
Infant
Male
South America
World Health Organization
Antiretroviral formulation
Pediatric HIV
Pediatric antiretroviral therapy
Weight-for-age
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
24 May 2020
24 May 2020
Historique:
received:
03
12
2019
accepted:
03
05
2020
entrez:
26
5
2020
pubmed:
26
5
2020
medline:
9
2
2021
Statut:
epublish
Résumé
Pediatric antiretroviral therapy (ART) for children with HIV (CHIV) must be dosed appropriately for children's changing weights as they grow. To inform accurate estimates of ART formulations and doses needed, we described weight-for-age distributions among CHIV on ART in the IeDEA global pediatric collaboration between 2004 and 2016, using data from six regions (East, West, Central, and Southern Africa, Asia-Pacific, and Central/South America and the Caribbean). Overall, 59,862 children contributed to the analysis. Age and weight data were available from 530,080 clinical encounters for girls and 537,894 for boys. For each one-year age stratum from 0 to 15 years, we calculated the proportion of children in each of the weight bands designated by the World Health Organization as relevant to pediatric ART formulations: 0 to < 3 kg, 3 to < 6 kg, 6 to < 10 kg, 10 to < 14 kg, 14 to < 20 kg, 20 to < 25 kg, 25 to < 30 kg, 30 to < 35 kg, 35 to < 40 kg, 40 to < 45 kg, 45 to < 50 kg, 50 to < 55 kg, 55 to < 60 kg, and ≥ 60 kg. Data are reported for the entire cohort, as well as stratified by sex and IeDEA region, calendar year of ART use, and duration on ART at time of assessment (< 12 or ≥ 12 months), provided in data tables. These data are critical to improve the accuracy of forecasting and procurement of pediatric ART formulations as the pediatric HIV epidemic and pediatric HIV treatment strategies evolve.
Identifiants
pubmed: 32448379
doi: 10.1186/s13104-020-05081-7
pii: 10.1186/s13104-020-05081-7
pmc: PMC7245795
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
249Subventions
Organisme : NIH HHS
ID : U01AI069923
Pays : United States
Organisme : NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NIH HHS
ID : U01AI069907
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD079214
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069919
Pays : United States
Organisme : NIH HHS
ID : U01AI096299
Pays : United States
Organisme : NIH HHS
ID : U01AI069919
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI124872
Pays : United States
Organisme : NIH HHS
ID : U01AI069911
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Références
PLoS Med. 2018 May 4;15(5):e1002565
pubmed: 29727458
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S22-S26
pubmed: 29994916
BMC Pediatr. 2016 Mar 15;16:41
pubmed: 26979974
J Int AIDS Soc. 2017 Jun 28;20(1):21952
pubmed: 28691433
Pediatrics. 2012 Oct;130(4):e966-77
pubmed: 22987878
AIDS. 2010 Jan 2;24(1):139-46
pubmed: 19940744
AIDS. 2015 Sep 24;29(15):2009-23
pubmed: 26355573
J Int AIDS Soc. 2013 Jan 15;16:17998
pubmed: 23336728
BMC Health Serv Res. 2014 May 02;14:201
pubmed: 24885453
AIDS. 2015 Jan 2;29(1):101-9
pubmed: 25562494
Pediatr Infect Dis J. 2015 Jul;34(7):e159-68
pubmed: 25955835